<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0011675'>Cardiac arrhythmias</z:hpo> cause significant morbidity and mortality in patients with <z:e sem="disease" ids="C0010068" disease_type="Disease or Syndrome" abbrv="">coronary heart disease</z:e>, <z:hpo ids='HP_0000822'>hypertension</z:hpo>, and congestive <z:hpo ids='HP_0001635'>cardiac failure</z:hpo> and in the elderly </plain></SENT>
<SENT sid="1" pm="."><plain><z:mp ids='MP_0001845'>Inflammation</z:mp>, oxidative injury, altered myocyte metabolism, extracellular matrix remodeling and <z:mp ids='MP_0003045'>fibrosis</z:mp> initiate and perpetuate <z:hpo ids='HP_0011675'>cardiac arrhythmias</z:hpo>, especially <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Enhanced myeloperoxidase (MPO) activity by infiltrating activated leukocytes could bind to myocardial cells and cause <z:mp ids='MP_0003045'>fibrosis</z:mp> resulting in the initiation and progression of <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Supplementation of eicosapentaenoic and <z:chebi fb="0" ids="36005">docosahexaenoic acids</z:chebi> (<z:chebi fb="113" ids="28364">EPA</z:chebi> and DHA, respectively) suppresses <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="113" ids="28364">EPA</z:chebi> and DHA form precursors to anti-inflammatory <z:chebi fb="23" ids="18059">lipid</z:chebi> molecules: <z:chebi fb="0" ids="6497">lipoxins</z:chebi>, resolvins, protectins and maresins that are known to suppress <z:mp ids='MP_0001845'>inflammation</z:mp>, have anti-fibrotic actions and inhibit MPO activity </plain></SENT>
<SENT sid="5" pm="."><plain>Hence, it is likely that leukocyte and/or myocardial deficiency of <z:chebi fb="113" ids="28364">EPA</z:chebi> and DHA and consequent reduced formation of <z:chebi fb="0" ids="6497">lipoxins</z:chebi>, resolvins, protectins and maresins enhance <z:mp ids='MP_0001845'>inflammation</z:mp> and MPO activity that leads to myocardial damage and <z:mp ids='MP_0003045'>fibrosis</z:mp> and initiation and progression of <z:hpo ids='HP_0011675'>cardiac arrhythmias</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Based on these evidences, I propose that <z:chebi fb="0" ids="6497">lipoxins</z:chebi>, resolvins and protectins function as endogenous anti-arrhythmic molecules and their stable synthetic analogs could be useful in the management of <z:hpo ids='HP_0011675'>cardiac arrhythmias</z:hpo> </plain></SENT>
</text></document>